on CROSSJECT (EPA:ALCJ)
Crossject: Details on Share Capital and Voting Rights as of November 30, 2024
Crossject, a specialty pharmaceutical company, has revealed the total number of voting rights and shares constituting its share capital as of November 30, 2024. In compliance with AMF regulations, the company is disclosing crucial information for its investors. The share capital is composed of 41,281,094 shares. This number is identical to that of the previous month, October 2024.
The total number of theoretical voting rights amounts to 51,059,559, while the exercisable voting rights are slightly lower, reaching 50,918,076. This difference is due to the shares deprived of voting rights, in particular those held by the company itself, amounting to 87,789, and those under liquidity contract, totaling 56,046. Thus, 143,835 shares do not have current voting rights.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news